Page 8 - Flipbook
P. 8
Characteristics Balar et al/Pembro Del Muro et al/Durva+Treme
n 54 32
Follow-up 15.5 months (1.6 – 56.5 m) 12.7 months (5.3 – 24.5 m)
Gender (male) 72% 78%
Clinical stage T2 – 70% T2 – 87%
T3 – 26% T3 – 9%
T4 – 4% T4 – 3%
Histology Pure UC – 97% Pure UC – 63%
Prior NMIBC 19% (BCG: 12%) 44% (BCG: 25%)
Response
CR 32 (59%) 26 (81%)
T0 response: 25 (78%)
NMIBC: 1 (3%)
Not evaluated 11 (20%) – all clinically with 4 (12.5%)
no evidence of disease
(clinical CR: 80%)
1-yr BIDFS in pts with CR 89% (95% CI 76-95%) 73% (95% CI 59-91%)
Radiation Oncology
